Goodwin
Daniel Karelitz
- Deals
- 10
- Latest
- Jun 2026
- Most deals in
- Biotech
Firm
- Goodwin Law firm · 2026 · 10 deals
Often works with
- Arman Oruc 6 deals together
- Andrea Akinbola 4 deals together
- Simone Waterbury 4 deals together
- Matthew Wetzel 4 deals together
- Felipe M. Heiderich 3 deals together
- Wei Xu 3 deals together
- Artimus Cunningham 3 deals together
- Sarah Bock 3 deals together
Deals
Deals dated after 30 September 2026 are still being collected.
Columns
| Jun 2026 | Alloy Enterprises | – | Johnson Controls | Acquisition | Legal adviser to Alloy Enterprises (target) | Announced | – | Manufacturing+2 | Johnson Controls acquisition of Alloy Enterprises |
| Jun 2026 | Topaz Labs | – | Adobe | Acquisition | Legal adviser to Topaz Labs (target) | Announced | – | AI | Adobe acquisition of Topaz Labs |
| May 2026 | LimmaTech Biologics AG | – | Eli Lilly and Company | Acquisition | Legal adviser to LimmaTech Biologics AG (target) | Pending | 780.0 | Biotech | Eli Lilly and Company acquisition of LimmaTech Biologics AG |
| Apr 2026 | Obsidian Therapeutics | – | – | Placement | Legal adviser to Obsidian Therapeutics | Completed | 350.0 | Biotech+2 | Obsidian Therapeutics placement |
| Apr 2026 | Obsidian Therapeutics | – | Galera Therapeutics | Merger | Legal adviser to Obsidian Therapeutics | Completed | 413.5 | Biotech+2 | Galera Therapeutics and Obsidian Therapeutics merger |
| Apr 2026 | Tubulis | EQT Life Sciences (LSP 7 fund) | Gilead Sciences | Acquisition | Legal adviser to Tubulis (target) | Announced | 3,150.0 | Biotech+2 | Gilead Sciences acquisition of Tubulis |
| Mar 2026 | Ouro Medicines | – | Gilead | Acquisition | Legal adviser to Ouro Medicines (target) | Announced | 1,675.0 | Biotech+1 | Gilead acquisition of Ouro Medicines |
| Feb 2026 | Bruder Consulting & Venture Group | – | Dark Horse Consulting Group | Acquisition | Legal adviser to Bruder Consulting & Venture Group (target) | Completed | – | Accounting, legal and consulting+1 | Dark Horse Consulting Group acquisition of Bruder Consulting & Venture Group |
| Feb 2026 | Laysan Bio | – | Gannet BioChem | Acquisition | Legal adviser to Gannet BioChem (acquirer) | Announced | – | Pharma Services+2 | Gannet BioChem acquisition of Laysan Bio |
| Feb 2026 | Orna Therapeutics | – | Eli Lilly and Company | Acquisition | Legal adviser to Orna Therapeutics (target) | Announced | 2,400.0 | Biotech+1 | Eli Lilly and Company acquisition of Orna Therapeutics |
Deals where Daniel Karelitz is named on the firm's deal team, by the firm or the press.